MUC1

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to significantly alleviate the financial burden of population-wide screening, offering more affordable Multi-Cancer Early Detection (MCED) tests. SeekIn also debuted the findings from its lung cancer early detection test study, marking a significant advancement in the field of cancer screening. SeekIn's two-step multi-cancer screening strategy SeekIn proposes a two-step MCED screening approach, beginning with cost-effective initial tests like OncoSeek®, followed by advanced secondary tests such as SeekInCare® for those who test positive. This two-step approach has the potential to significantly reduce the financial burden compared to using NGS-based MCED tests for population-level screening. In a study with 1,197 participants (617 with cancer and 580 without), the two-step MCED approach achieved a remarkable 12.9-fold reduction in the false positive rate, from 9.0% to 0.7%. When applied to a hypothetical screening of five million adults, the strategy reduced total cost by 6.6-fold ($713.6 million compared to $4,745 million) and cost per cancer patient identified by 5.2-fold ($33,534 compared to $172,828), offering significant savings over an NGS-based MCED test to screen five million adults. Lung cancer early detection with LungCanSeek® SeekIn also presented its LungCanSeek® test, a blood-based, non-invasive, and cost-effective solution for lung cancer early detection. In a study of 1,814 participants (1,095 with lung cancer and 719 without cancer) from three cohorts, LungCanSeek showed 83.5% sensitivity and 90.3% specificity by combining artificial intelligence (AI) algorithms with four protein tumor markers (PTMs). Moreover, LungCanSeek can also predict the possible histological subtypes. With a 77.4% subtype classification accuracy, it could offer valuable guidance for subsequent diagnosis and treatment. For lung cancer screening, SeekIn also recommends a two-step strategy: initial screening with LungCanSeek, followed by low-dose computed tomography (LDCT) imaging for positive cases. This integrated approach leverages the strengths of both tests, reducing false positives by over 10-fold and costs by 2.5-fold compared to sole LDCT screening in high-risk populations. About OncoSeek® OncoSeek® has been developed as a multi-cancer detection test that uses artificial intelligence to distinguish between cancer patients and non-cancer individuals by calculating the probability of cancer (POC) index based on the plasma levels of seven PTMs (i.e. AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1), gender and age of the subjects. OncoSeek® is a non-invasive, efficient, and cost-effective approach for multi-cancer early detection. OncoSeek® received CE-IVD Mark in September 2022. About SeekInCare® With the mission to detect cancer while it is still curable, SeekInCare® has been developed as a pan-cancer detection test that takes a panoramic view of blood cell-free cancer signatures and a multi-omics approach incorporating genomic and epigenetic alterations in conjunction with clinically validated protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare exhibits superior effectiveness to detect dozens of cancer types at high specificity. SeekInCare is intended for use in individuals with elevated risks of cancer such as smoking, chronic hepatitis, aging, etc., in conjunction with the approved conventional single-cancer type screening tests. SeekInCare received CE-IVD Mark in November 2021. About LungCan Seek ® LungCanSeek® was developed to distinguish lung cancer patients from non-cancer individuals and predict potential histological subtypes, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and small cell lung cancer (SCLC). The test employs AI algorithms based on four PTMs, along with the subject's gender and age. It represents a non-invasive, efficient, and cost-effective approach for the early detection of lung cancer. About SeekIn SeekIn Inc is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing next-generation sequencing and artificial intelligence. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn has also developed novel molecular tests for leukemia patients and its cancer early detection technology has also successfully been applied to canines. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in China. SeekIn envisions that, by leading a new norm for cancer early detection, the clinical outcomes of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn's cutting-edge technologies and products, visit . SOURCE SeekIn Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

FRIDAY, Sept. 6, 2024 -- A computed tomography (CT)-based radiomics nomogram model can achieve favorable efficacy for predicting low-risk patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), according to a study published online July 31 in Frontiers in Immunology . Nie Han, from Guanghua Hospital Affiliated to the Shanghai University of Traditional Chinese Medicine, and colleagues retrospectively analyzed chest CT images of patients with RA-ILD and staged them using the ILD-gender, age, and pulmonary physiology index system. The dataset with 177 patients was divided into training and testing cohorts in a 7:3 ratio, respectively. A nomogram model was established based on the Rad-score and clinical factors, combined with the radiomics signature and independent clinical factors. The nomogram was built using the Krebs von den Lungen-6 (KL-6) and nineteen radiomics features. The researchers found that calibration and discrimination of the model were favorable in the training and testing validation cohorts (areas under the receiver operating characteristic curve, 0.948 and 0.923, respectively). In terms of clinical usefulness, the nomogram performed well in a decision curve analysis. "A novel nomogram model combining CT-based radiomics and serum KL-6 was developed in our study," the authors write. "It shows good prediction accuracy in predicting low-risk RA-ILD patients, which implies that this noninvasive and quantitative method may impact the clinical decision-making process, offering a more precise management strategy for patients with RA-ILD." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options. Globally, breast cancer continues to be the most prevalent malignancy in women. Among all subtypes, triple-negative breast cancer (TNBC) stands out as the most aggressive form with high metastatic potential and poor survival rates. Despite a few emerging targeted therapies under investigation, surgery, chemotherapy and radiation therapy continue to be the standard of care, and their success remains limited. As an alternative, Chimeric Antigen Receptor (CAR) T-cell therapies could hold promise for advance-stage TNBC patients as tumor-associated MUC1 antigen is overexpressed in a large number of patients thus offering a distinct target for treatment. In this article, Cellectis described its multi-layered CAR T-cell engineering strategy using TALEN® and synthetic biology to multi-armor CAR T-cells with synergistic functionalities to overcome the immunosuppressive tumor microenvironment (TME) of solid tumors. With this strategy, Cellectis demonstrates enhanced cytotoxic activity of MUC1 CAR T-cells armored with PD1KO, tumor-specific IL12 release and TGFBR2KO attributes, all of them catered towards the TNBC TME, in intravenous and intratumoral mouse models. “Complexity of solid tumors decreases the efficacy of CAR T-cell therapies. With this pre-clinical study, we showed that TALEN®-mediated multiplex editing can support CAR T-cells in effectively mounting an anti-tumor response to clear breast tumors, and that we can further decrease the dose of the treatment by injecting the CAR T cells intratumorally while still treating distant tumors. This innovative approach also allowed us to discover an unexpected cooperation between the edits in increasing safety, highlighting the potential capabilities of multiplex editing” said Piril Erler, PhD, Scientist II at Cellectis. Importantly, intratumoral treatment effectively reduced local and distant tumors of large size using low doses of multi-armored MUC1 CAR T-cells. This pre-clinical data suggests that the benefits of antigen recognition are maintained at distant sites and highlights the potential to address metastasis with local administration. The article is available on Science Advances’ website by clicking on this link: About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN ® , its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit our website: Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter) TALEN® is a registered trademark owned by Cellectis. Forward-looking Statements This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “"can,” “possibility,” and “suggest” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, include statements about the potential of the product candidate MUC1, and reproducibility of these preclinical data on humans. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com Attachment MUC1 paper press release